Biomarker-Targeted O6-Guanine Alkylation Potentiates ATR Inhibitor Response in De Novo and Relapsed/Refractory AML
Prateek Bhardwaj, Amro Baassiri, Ranjini K. Sundaram, Sam Friedman, James Elia, Jennifer VanOudenhove, Collin Heer, Ahmad Kiwan, Martin Matthews, Susan E. Gueble, Stephanie Halene, Ranjit S. Bindra
This study identifies MGMT silencing as a therapeutic target in AML and shows that combining O6-fluoroethylating agents with ATR inhibitors improves treatment outcomes.
bioRxiv · Sep 22, 2026 · PreprintCancer Biology